My ePortfolio Register   

ESMO 2017 /
ESMO 2017 roundup with Dr Bishal Gyawali (2/2)

8th - 12th Sep 2017

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 11.09.17
Views: 2572
Rating:

Dr Bishal Gyawali - Nagoya University, Nagoya, Japan

Dr Gyawali speaks with ecancer reporter Will Davies about highlights from ESMO 2017.

Throughout, Dr Gyawali keeps patient-centric endpoints including quality of life and overall survival as the focus, noting the promise of many trials in extending progression free survival and response, but cautioning that this may not translate to longer, better lives for patients.

Part one of his round up, looking at highlights in melanoma, prostate cancer and kidney cancer is available here.

For more on LORELEI and ExteNET, watch Prof Miguel Martins comment on the results here.

For more on MONARCH 3 and abemaciclib from Dr Angelo di Leo, click here.

For more on letrozole and palbociclib in luminal cancer, click here.

For more on the role of chemoradiation for ovarian cancer from Dr Sudeep Gupta, click here.

For more on the PACIFIC trial of durvalumab in lung cancer, click here.

For more on the use of CT scans after lung cancer surgery, click here.

For more on the use of osimertinib in the FLAURA trial, click here.

For more on pembrolizumab in KEYNOTE 40, click here.

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence